For those unfamiliar with Hatch-Waxman, PLI's "Lawyer's Toolbox" is offering "The FTC's Pharmaceutical Cases" by Jeffrey W. Brennan of the Bureau of Competition at the Federal Trade Commission). Brennan's PowerPoint offers the legislation's rationale, stunning statistics about the efficacy of generics in lowering drug costs and brief overviews of the FTC's recent decision in the case involving Schering-Plough. Also available is "New Strategies Arising From the Hatch-Waxman Amendments" by Michael P. Padden of Howrey Simon Arnold & White, LLP with an overview of the current state of pharmaceutical development.
Rodney D. Ryder
No comments:
Post a Comment